- Approval Id
- 3216999d4df272c5
- Drug Approval Emc Name
- Scemblix 40 mg film-coated tablets
- Drug Name
- Scemblix 40 mg film-coated tablets
- Company Name
- Novartis Pharmaceuticals UK Ltd
- Company Address
- 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
- Company Telephone
- +44 (0)1276 692 255
- Company Medical Info Direct Line
- +44 (0)1276 698 370
- Company Medical Info Email
- medinfo.uk@novartis.com
- Company Customer Care Direct Line
- +44 (0)845 741 9442
- Atc Code
- L01EA06
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Novartis Pharmaceuticals UK Limited
2nd Floor, The WestWorks Building, White City Place
195 Wood Lane
London
W12 7FQ
United Kingdom
- Authorisation Number
- Scemblix 20 mg film-coated tablets - PLGB 00101/1207
Scemblix 40 mg film-coated tablets - PLGB 00101/1208
- Authorisation Date
- 15/06/2022
- Instruction Authorisation Holder
- Novartis Pharmaceuticals UK Limited
2nd Floor, The WestWorks Building, White City Place
195 Wood Lane
London
W12 7FQ
United Kingdom
- Instruction Authorisation Number
- Scemblix 20 mg film-coated tablets - PLGB 00101/1207
Scemblix 40 mg film-coated tablets - PLGB 00101/1208
- Instruction Authorisation Date
- 15/06/2022
- Instruction Composition
- \*\*Scemblix 20 mg film-coated tablets\*\*
Each film-coated tablet contains asciminib hydrochloride, equivalent to 20 mg asciminib.
\*\*\*Excipients with known effect\*\*\*
Each film-coated tablet contains 43 mg lactose monohydrate.
\*\*Scemblix 40 mg film-coated tablets\*\*
Each film-coated tablet contains asciminib hydrochloride, equivalent to 40 mg asciminib.
\*\*\*Excipients with known effect\*\*\*
Each film-coated tablet contains 86 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Film-coated tablet.
\*\*20 mg film-coated tablets\*\*
Pale yellow, round, biconvex film-coated tablets with bevelled edges of approximately 6 mm diameter, unscored, debossed with company logo on one side and “20” on the other side.
\*\*Scemblix 40 mg film-coated tablets\*\*
Violet white, round, biconvex film-coated tablets with bevelled edges of approximately 8 mm diameter, unscored, debossed with company logo on one side and “40” on the other side.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.4.2 Posology and method of administration
Treatment with Scemblix should be initiated by a physician knowledgeable in the diagnosis and treatment of patients with chronic myeloid leukaemia.
\*\*Posology\*\*
The recommended total daily dose of Scemblix is 80 mg. Scemblix can be taken orally either as 80 mg once daily at approximately the same time each day or as 40 mg twice daily at approximately 12-hour intervals.
Patients changing from 40 mg twice daily to 80 mg once daily should start taking asciminib once daily approximately 12 hours after the last twice-daily dose, and then continue at 80 mg once daily.
Patients changing from 80 mg once daily to 40 mg twice daily should start taking asciminib twice daily approximately 24 hours after the last once-daily dose and then continue at 40 mg twice daily at approximately 12-hour intervals.
Any change in the dosage regimen is at the prescriber's discretion, as necessary for the management of the patient.
\*\*\*Missed dose\*\*\*
Once-daily dosage regimen: If a dose is missed by more than approximately 12 hours, it should be skipped and the next dose should be taken as scheduled.
Twice-daily dosage regimen: If a dose is missed by more than approximately 6 hours, it should be skipped and the next dose should be taken as scheduled.
\*\*\*Treatment duration\*\*\*
Treatment with asciminib should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs.
\*\*\*Dose adjustments for adverse reactions\*\*\*
For the management of adverse reactions, the dose can be reduced based on individual safety and tolerability, as described in Table 1.
If adverse reactions are effectively managed, asciminib may be resumed as described in Table 1. It should be permanently discontinued in patients unable to tolerate a total daily dose of 40 mg.
\*\*Table 1 Asciminib dose modification\*\*
| | | |
| --- | --- | --- |
| \*\*Starting dose\*\* | \*\*Reduced dose\*\* | \*\*Resumed dose\*\* |
| 80 mg once daily | 40 mg once daily | 80 mg once daily |
| 40 mg twice daily | 20 mg twice daily | 40 mg twice daily |
The recommended dosage modification for the management of selected adverse reactions is shown in Table 2.
\*\*Table 2 Asciminib dose modification schedule for the management of adverse reactions\*\*
| | |
| --- | --- |
| \*\*Adverse reaction\*\* | \*\*Dosage modification\*\* |
| \*\*Thrombocytopenia and/or neutropenia\*\* | |
| ANC <1.0 x 109/l and/or PLT <50 x 109/l | Withhold asciminib until resolved to ANC ≥1 x 109/l and/or PLT ≥50 x 109/l. If resolved: • Within 2 weeks: resume at starting dose. • After more than 2 weeks: resume at reduced dose For recurrent severe thrombocytopenia and/or neutropenia, withhold asciminib until resolved to ANC ≥1 x 109/l and PLT ≥50 x 109/l, then resume at reduced dose. |
| \*\*Asymptomatic amylase and/or lipase elevation\*\* | |
| Elevation >2.0 x ULN | Withhold asciminib until resolved to <1.5 x ULN. • If resolved: resume at reduced dose. If events reoccur at reduced dose, permanently discontinue. • If not resolved: permanently discontinue. Perform diagnostic tests to exclude pancreatitis. |
| \*\*Non-haematological adverse reactions\*\* | |
| Grade 3 or higher adverse reactions1 | Withhold asciminib until resolved to grade 1 or lower. • If resolved: resume at a reduced dose. • If not resolved: permanently discontinue |
| ANC: absolute neutrophil count; PLT: platelets; ULN: upper limit of normal 1Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03. | |
\*\*\*Special populations\*\*\*
\*Elderly\*
No dose adjustment is required in patients aged 65 years or above.
\*Renal impairment\*
No dose adjustment is required in patients with mild, moderate or severe renal impairment (see section 5.2).
\*Hepatic impairment\*
No dose adjustment is required in patients with mild, moderate or severe hepatic impairment (see section 5.2). Since there are no data available in patients with moderate or severe hepatic impairment, caution should be exercised in these patients (see section 4.8 and 5.2).
\*Paediatric population\*
The safety and efficacy of Scemblix in paediatric patients aged below 18 years have not been established. No data are available.
\*\*Method of administration\*\*
Scemblix is for oral use. The tablets should be taken orally without food. Food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib (see sections 4.5 and 5.2).
The film-coated tablets should be swallowed whole with a glass of water and should not be broken, crushed or chewed.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Myelosuppression\*\*
Thrombocytopenia, neutropenia and anaemia occurred in patients receiving asciminib. Severe (NCI CTCAE grade 3 or 4) thrombocytopenia and neutropenia were reported during treatment with asciminib (see section 4.8). Myelosuppression was generally reversible and managed by temporarily withholding treatment. Complete blood counts should be performed every two weeks for the first 3 months of treatment and then monthly thereafter, or as clinically indicated. Patients should be monitored for signs and symptoms of myelosuppression.
Based on the severity of thrombocytopenia and/or neutropenia, the dose should be temporarily withheld, reduced or permanently discontinued (see section 4.2).
\*\*Pancreatic toxicity\*\*
Pancreatitis and asymptomatic elevation of serum lipase and amylase, including severe reactions, occurred in patients receiving asciminib (see section 4.8).
Serum lipase and amylase levels should be assessed monthly during treatment with asciminib, or as clinically indicated. Patients should be monitored for signs and symptoms of pancreatic toxicity. More frequent monitoring should be performed in patients with a history of pancreatitis. If serum lipase and amylase elevation are accompanied by abdominal symptoms, treatment should be temporarily withheld and appropriate diagnostic tests should be considered to exclude pancreatitis (see section 4.2).
Based on the severity of serum lipase and amylase elevation, the dose should be temporarily withheld, reduced or permanently discontinued (see section 4.2).
\*\*QT prolongation\*\*
QT prolongation occurred in patients receiving asciminib (see section 4.8).
It is recommended that an electrocardiogram is performed prior to the start of treatment with asciminib, and monitored during treatment as clinically indicated. Hypokalaemia and hypomagnesaemia should be corrected prior to asciminib administration and monitored during treatment as clinically indicated.
Caution should be exercised when administering asciminib concomitantly with medicinal products with a known risk of torsades de pointes, or in patients who have a history of or predisposition for QTc prolongation or uncontrolled or significant cardiac disease including bradycardia (see sections 4.5 and 5.1).
\*\*Hypertension\*\*
Hypertension, including severe hypertension, occurred in patients receiving asciminib (see section 4.8).
Hypertension should be monitored and managed using standard antihypertensive therapy during treatment with asciminib as clinically indicated.
\*\*Hepatitis B reactivation\*\*
Reactivation of hepatitis B virus (HBV) has occurred in patients who are chronic carriers of this virus following administration of other BCR::ABL1 tyrosine kinase inhibitors (TKIs). Patients should be tested for HBV infection before the start of treatment with asciminib. HBV carriers who require treatment with asciminib should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
\*\*Lactose\*\*
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
\*\*Sodium\*\*
This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially “sodium free”.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Medicinal products that may decrease asciminib plasma concentrations\*\*
\*\*\*Strong CYP3A4 inducers\*\*\*
Co-administration of a strong CYP3A4 inducer in healthy subjects decreased asciminib AUCinf by 14.9% and increased Cmax by 9% in healthy subjects receiving a single asciminib dose of 40 mg. Physiologically-based pharmacokinetic (PBPK) models predict that co-administration of asciminib at 80 mg once daily with rifampicin would decrease asciminib AUCtau and Cmax by 52% and 23%.
Caution should be exercised during concomitant administration of asciminib with strong CYP3A inducers, including, but not limited to, carbamazepine, phenobarbital, phenytoin or St. John's wort (\*Hypericum perforatum\*). Dose adjustment of asciminib is not required.
\*\*Medicinal products that may have their plasma concentrations altered by asciminib\*\*
\*\*\*CYP3A4 substrates with narrow therapeutic index\*\*\*
Co-administration of asciminib with a CYP3A4 substrate (midazolam) increased midazolam AUCinf and Cmax by 28% and 11%, respectively, in healthy subjects receiving asciminib 40 mg twice daily. PBPK models predict that co-administration of asciminib at 80 mg once daily would increase midazolam AUCinf and Cmax by 24% and 17%, respectively.
Caution should be exercised during concomitant administration of asciminib with CYP3A4 substrates known to have a narrow therapeutic index, including, but not limited to, the CYP3A4 substrates fentanyl, alfentanil, dihydroergotamine or ergotamine (see section 5.2). Dose adjustment of asciminib is not required.
\*\*\*CYP2C9 substrates\*\*\*
Co-administration of asciminib with a CYP2C9 substrate (warfarin) increased S-warfarin AUCinf and Cmax by 41% and 8%, respectively, in healthy subjects receiving asciminib 40 mg twice daily. PBPK models predict that co-administration of asciminib at 80 mg once daily would increase S-warfarin AUCinf and Cmax by 52% and 4%, respectively.
Caution should be exercised during concomitant administration of asciminib with CYP2C9 substrates known to have a narrow therapeutic index, including, but not limited to, phenytoin or warfarin (see section 5.2). Dose adjustment of asciminib is not required.
\*\*\*P-gp substrates of narrow therapeutic index\*\*\*
Caution should be exercised during concomitant administration of asciminib with P-gp substrates known to have a narrow therapeutic index, including but not limited to digoxin, dabigatran and colchicine (see section 5.2). Dose adjustment of asciminib is not required.
\*\*\*P-gp substrates\*\*\*\*\*:\*\*
Coadministration of SCEMBLIX with a drug that is a substrate of P-gp may result in a clinically relevant increase in the plasma concentrations of P-gp substrates, where minimal concentration changes may lead to serious toxicities (e.g. P-gp substrates with narrow therapeutic index such as digoxin).
\*\*\*QT prolongation\*\*\*
Caution should be exercised during concomitant administration of asciminib and medicinal products with a known risk of torsades de pointes, including, but not limited to, bepridil, chloroquine, clarithromycin, halofantrine, haloperidol, methadone, moxifloxacin or pimozide (see sections 4.4, 4.8 and 5.1).
\*\*\*Drug-food interactions\*\*\*
The bioavailability of asciminib decreases on consumption of food (see sections 4.2 and 5.2).
\*\*\*Hydroxypropyl-β-cyclodextrin as an excipient (e.g., itraconazole oral solution)\*\*\*
Caution should be exercised during concomitant administration of asciminib with hydroxypropyl-β-cyclodextrin containing oral products (see section 5.2).4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential/contraception\*\*
The pregnancy status of women of childbearing potential should be verified prior to starting treatment with asciminib.
Women of childbearing potential should be advised to use effective contraception during treatment with asciminib and for at least 3 days after stopping treatment and to avoid becoming pregnant while receiving asciminib.
\*\*Pregnancy\*\*
There are no or limited amount of data from the use of asciminib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Asciminib is not recommended for use during pregnancy, or in women of childbearing potential not using contraception. The patient should be advised of a potential risk to the foetus if asciminib is used during pregnancy or if the patient becomes pregnant while taking asciminib.
\*\*Breast-feeding\*\*
It is unknown whether asciminib is excreted in human milk. There are no data on the effects of asciminib on the breast-fed newborn/infant or on milk production. Because of the potential for serious adverse reactions in the breast-fed newborn/infant, breast-feeding is not recommended during treatment and for at least 3 days after stopping treatment with asciminib.
\*\*Fertility\*\*
There are no data on the effect of asciminib on human fertility. In rat fertility studies, asciminib did not affect reproductive function in male and female rats (see section 5.3).4.7 Effects on ability to drive and use machines
Asciminib has no or negligible influence on the ability to drive and use machines. However, it is recommended that patients experiencing dizziness, fatigue or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8).4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The overall safety profile of asciminib has been evaluated in 356 patients with Ph+ CML-in chronic (CP) and accelerated (AP) phases in the pivotal phase III study A2301 (ASCEMBL) and the phase I study X2101. In ASCEMBL, patients received asciminib as monotherapy at a dose of 40 mg twice daily. In X2101, patients received asciminib as monotherapy at doses ranging from 10 to 200 mg twice daily and 80 to 200 mg once daily.
The safety pool (N=356) includes patients receiving asciminib at doses ranging from 10 to 200 mg twice daily and 80 to 200 mg once daily, with 156 patients receiving asciminib at 40 mg twice daily in the pivotal study, and 35 patients receiving 40 mg twice daily and 18 patients receiving 80 mg once daily from study X2101 as a starting dose. In the pooled dataset, the median duration of exposure to asciminib was 167 weeks (range: 0.1 to 349 weeks).
The most common adverse reactions of any grade (incidence ≥20%) in patients receiving asciminib were musculoskeletal pain (38.8%), upper respiratory tract infections (29.5%), fatigue (28.9%), thrombocytopenia (28.1%), headache (26.4%), arthralgia (24.4%), increased pancreatic enzymes (23%), diarrhoea (22.5%), abdominal pain (22.2%), rash (21.6%), hypertension (20.8%) and nausea (20.8%).
The most common adverse reactions of ≥ grade 3 (incidence ≥5%) in patients receiving asciminib were thrombocytopenia (18.5%), neutropenia (15.7%), increased pancreatic enzymes (12.94%), hypertension (11.2%) and anaemia (5.3%).
Serious adverse reactions occurred in 13.2% of patients receiving asciminib. The most frequent serious adverse reactions (incidence ≥1%) were pleural effusion (2.5%), lower respiratory tract infections (2.2%), thrombocytopenia (1.7%), pyrexia (1.4%), pancreatitis (1.1%), abdominal pain (1.1%), non-cardiac chest pain (1.1%) and vomiting (1.1%). The predicted safety profile of asciminib at the 80 mg once-daily dose is similar to the 40 mg twice-daily dose, based on exposure-safety analysis.
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions from clinical studies (Table 3) are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
\*\*Table 3 Adverse reactions observed with asciminib in clinical studies\*\*
| | | |
| --- | --- | --- |
| \*\*System organ class\*\* | \*\*Frequency category\*\* | \*\*Adverse reaction\*\* |
| Infections and infestations | Very common | Upper respiratory tract infection1 |
| Common | Lower respiratory tract infection2, influenza |
| Blood and lymphatic system disorders | Very common | Thrombocytopenia3, neutropenia4, anaemia5 |
| Uncommon | Febrile neutropenia, pancytopenia |
| Immune system disorders | Uncommon | Hypersensitivity |
| Metabolism and nutrition disorders | Very common | Dyslipidaemia6 |
| Common | Decreased appetite |
| Nervous system disorders | Very common | Headache, dizziness |
| Eye disorders | Common | Dry eye, vision blurred |
| Cardiac disorders | Common | Palpitations |
| Vascular disorders | Very common | Hypertension7 |
| Respiratory, thoracic and mediastinal disorders | Very common | Dyspnoea, cough |
| Common | Pleural effusion, non-cardiac chest pain |
| Gastrointestinal disorders | Very common | Pancreatic enzymes increased8, vomiting, diarrhoea, nausea, abdominal pain9,, constipation |
| Common | Pancreatitis10 |
| Hepatobiliary disorders | Very common | Hepatic enzyme increased11 |
| Common | Blood bilirubin increased12 |
| Skin and subcutaneous tissue disorders | Very common | Rash13, pruritis |
| Common | Urticaria |
| Musculoskeletal and connective tissue disorders | Very common | Musculoskeletal pain14, arthralgia |
| General disorders and administration site conditions | Very common | Fatigue15, oedema16, pyrexia17 |
| Investigations | Common | Electrocardiogram QT prolonged, blood creatine phosphokinase increased |
| 1 Upper respiratory tract infection includes: upper respiratory tract infection, nasopharyngitis, pharyngitis and rhinitis. 2 Lower respiratory tract infections includes: pneumonia, bronchitis and tracheobronchitis. 3 Thrombocytopenia includes: thrombocytopenia and platelet count decreased 4 Neutropenia includes: neutropenia and neutrophil count decreased 5 Anaemia includes: anaemia, haemoglobin decreased and normocytic anaemia. 6 Dyslipidaemia includes: hypertriglyceridaemia, blood cholesterol increased, hypercholesterolaemia, blood triglycerides increased, hyperlipidaemia and dyslipidaemia. 7 Hypertension includes: hypertension and blood pressure increased. 8 Pancreatic enzymes increased includes: lipase increased, amylase increased and hyperlipasaemia. 9 Abdominal pain includes: abdominal pain and abdominal pain upper. 10 Pancreatitis includes: pancreatitis and pancreatitis acute. 11 Hepatic enzymes increased includes: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, transaminases increased and hypertransaminasaemia. 12 Blood bilirubin increased includes: blood bilirubin increased, bilirubin conjugated increased and hyperbilirubinaemia. 13 Rash includes: rash, rash maculopapular and rash pruritic. 14 Musculoskeletal pain includes: pain in extremity, back pain, myalgia, bone pain, musculoskeletal pain, neck pain, musculoskeletal chest pain and musculoskeletal discomfort. 15 Fatigue includes: fatigue and asthenia. 16 Oedema includes: oedema and oedema peripheral. 17 Pyrexia includes: pyrexia and body temperature increased. | | |
\*\*Description of selected adverse reactions\*\*
\*\*\*Myelosuppression\*\*\*
Thrombocytopenia occurred in 28.1% patients receiving asciminib, with grade 3 and 4 reactions reported in 6.7% and 11.8% of patients, respectively. Among the patients with thrombocytopenia ≥ grade 3, the median time to first occurrence of reactions was 6.14 weeks (range: 0.14 to 64.14 weeks) with median duration of any occurring reaction of 2 weeks (95% CI, range: 1.43 to 2 weeks). Of the patients with thrombocytopenia, 2.5% permanently discontinued asciminib, while asciminib was temporarily withheld in 12.4% patients due to the adverse reaction.
Neutropenia occurred in 19.7% patients receiving asciminib, with grade 3 and 4 reactions reported in 7.3% and 8.4% of patients, respectively. Among the patients with neutropenia ≥ grade 3, the median time to first occurrence of reactions was 6.14 weeks (range: 0.14 to 180.1 weeks) with median duration of any occurring reaction of 2 weeks (95% CI, range: 1.43 to 2.14 weeks). Of the patients with neutropenia, 1.7% patients permanently discontinued asciminib, while asciminib was temporarily withheld in 9.3% patients due to the adverse reaction.
Anaemia occurred in 13.2% patients receiving asciminib, with grade 3 reactions occurring in 5.3% of patients. Among the patients with anaemia ≥ grade 3, the median time to first occurrence of reactions was 30.43 weeks (range: 0.43 to 207 weeks) with median duration of any occurring reaction of 0.86 weeks (95% CI, range: 0.29 to 1.71 weeks). Of the patients with anaemia, asciminib was temporarily withheld in 0.6% of patients due to the adverse reaction (see section 4.4).
\*\*\*Pancreatic toxicity\*\*\*
Pancreatitis occurred in 2.5% of patients receiving asciminib, with grade 3 reactions occurring in 1.1% of patients. All these reactions occurred in the phase I study (X2101). Of the patients with pancreatitis, 0.6% permanently discontinued asciminib, while asciminib was temporarily withheld in 1.4% of patients due to the adverse reaction. Asymptomatic elevations of serum lipase and amylase occurred in 23% of patients receiving asciminib, with grade 3 and 4 reactions occurring in 10.4% and 2.5% patients, respectively. Of the patients with elevation of pancreatic enzymes, asciminib was permanently discontinued in 2.2% of patients due to the adverse drug reaction. (see section 4.4)
\*\*\*QT prolongation\*\*\*
Electrocardiogram QT prolongation occurred in 1.1% patients receiving asciminib. In the ASCEMBL clinical study, one patient had a prolonged QTcF greater than 500 ms together with more than 60 ms QTcF increase from baseline, and another patient had prolonged QTcF with more than 60 ms QTcF increase from baseline. (See sections 4.4, 4.5 and 5.1).
\*\*\*Hypertension\*\*\*
Hypertension occurred in 20.8% of patients receiving asciminib, with grade 3 and 4 reactions reported in 11% and 0.3% patients, respectively. Among the patients with hypertension ≥ grade 3, the median time to first occurrence of reactions was 29.21 weeks (range: 0.14 to 365 weeks). Of the patients with hypertension, asciminib was temporarily withheld in 0.8% of patients due to the adverse reaction (see section 4.4).
\*\*\*Laboratory abnormalities\*\*\*
Decrease in phosphate levels occurred as a laboratory abnormality in 17.9% (all grades) and 7.1% (grade 3/4) of 156 patients receiving asciminib at 40 mg twice daily.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
There is limited experience of asciminib overdose. In clinical studies, asciminib has been administered at doses up to 280 mg twice daily with no evidence of increased toxicity.
General supportive measures and symptomatic treatment should be initiated in cases of suspected overdose.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors. ATC code: L01EA06
\*\*Mechanism of action\*\*
Asciminib is an oral and potent inhibitor of ABL and BCR::ABL1 tyrosine kinases. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein, by specifically targeting the ABL myristoyl pocket.
\*\*Cardiac electrophysiology\*\*
Asciminib treatment is associated with an exposure-related prolongation of the QT interval.
The correlation between asciminib concentration and the estimated mean change from baseline of the QT interval with Fridericia's correction (ΔQTcF) was evaluated in 239 patients with Ph+ CML or Ph+ acute lymphoblastic leukaemia (ALL) receiving asciminib at doses ranging from 10 to 280 mg twice daily and 80 to 200 mg once daily. The estimated mean ΔQTcF was 3.35 ms (upper bound of 90% CI: 4.43 ms) for the asciminib 40 mg twice-daily dose and 3.64 ms (upper bound of 90% CI: 4.68 ms) for the asciminib 80 mg once daily dose (see sections 4.4, 4.5 and 4.8).
\*\*Clinical efficacy and safety\*\*
\*\*\*Ph+ CML-CP\*\*\*
The clinical efficacy and safety of asciminib in the treatment of patients with Philadelphia chromosome-positive myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors were demonstrated in the multicentre, randomised, active-controlled and open-label phase III study ASCEMBL.
In this study, a total of 233 patients were randomised in a 2:1 ratio and stratified according to major cytogenetic response (MCyR) status at baseline to receive either asciminib 40 mg twice daily (N=157) or bosutinib 500 mg once daily (N=76). Patients continued treatment until unacceptable toxicity or treatment failure occurred. Patients with known presence T315I and/or V299L mutations at any time prior to study entry were not included in ASCEMBL.
Patients with Ph+ CML-CP were 51.5% female and 48.5% male with median age 52 years (range: 19 to 83 years). Of the 233 patients, 18.9% were 65 years or older, while 2.6% were 75 years or older.
Patients were Caucasian (74.7%), Asian (14.2%) and Black (4.3%). Of the 233 patients, 80.7% and 18% had Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, respectively.
Patients who had previously received 2, 3, 4, 5 or more prior lines of TKIs were 48.1%, 31.3%, 14.6% and 6%, respectively. Last TKI was discontinued due to lack of efficacy in 63.9% of patients and to lack of tolerability in 34.8%.
The median duration of treatment was 156 weeks (range: 0.1 to 256.3 weeks) for patients receiving asciminib and 30.5 weeks (range: 1 to 239.3 weeks) for patients receiving bosutinib.
\*Results\*
The primary endpoint of the study was major molecular response rate (MMR) at 24 weeks and the key secondary endpoint was MMR rate at 96 weeks. MMR is defined as BCR::ABL1 IS ratio ≤0.1%. Other secondary endpoints were complete CCyR rate at 24 and 96 weeks, defined as no Philadelphia positive metaphases in bone marrow with a minimum of 20 metaphases examined.
The main efficacy outcomes from the ASCEMBL study are summarised in Table 4.
\*\*Table 4 Efficacy results in patients treated with two or more tyrosine kinase inhibitors (ASCEMBL)\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Efficacy results in patients treated with two or more tyrosine kinase inhibitors (ASCEMBL)\*\* | \*\*40 mg Scemblix twice daily\*\* | \*\*500 mg bosutinib once daily\*\* | \*\*Difference (95% CI)1\*\* | \*\*p-value\*\* |
| MMR rate, % (95% CI) at 24 weeks | \*\*N=157\*\* 25.48 (18.87, 33.04) | \*\*N=76\*\* 13.16 (6.49, 22.87) | 12.24 (2.19, 22.30) | 0.0292 |
| MMR rate, % (95% CI) at 96 weeks | \*\*N = 157\*\* 37.58 (29.99, 45.65) | \*\*N = 76\*\* 15.79 (8.43, 25.96) | 21.74 (10.53, 32.95) | 0.0012 |
| CCyR rate, % (95% CI) at 24 weeks | \*\*N=103\*\*3 40.78 (31.20, 50.9) | \*\*N=62\*\*3 24.19 (14.22, 36.74) | 17.3 (3.62, 30.99) | not formally tested |
| CCyR rate, % (95% CI) at 96 weeks | \*\*N = 1033\*\* 39.81 (30.29, 49.92) | \*\*N = 623\*\* 16.13 (8.02, 27.67) | 23.87 (10.30, 37.43) | not formally tested |
| Major molecular response (MMR) is defined as a BCR::ABL1 ratio ≤0.1% on the International Scale. Complete cytogenetic response (CCyR) is defined as no Philadelphia chromosome metaphases in bone marrow with a minimum of 20 metaphases examined. \*1 Adjusted for the baseline major cytogenetic response status\* \*2 Cochran-Mantel-Haenszel two-sided test stratified by baseline major cytogenetic response status\* \*3 CCyR analysis based on patients who were not in CCyR at baseline\* | | | | |
The predicted MMR rate at 24 weeks for the asciminib 80 mg once-daily dose is comparable to the MMR rate at 24 weeks observed in ASCEMBL with the asciminib 40 mg twice-daily dose, based on exposure response analysis.
In ASCEMBL, 12.7% of patients treated with asciminib and 13.2% of patients receiving bosutinib had one or more BCR::ABL1 mutations detected at baseline. MMR rates by mutation status are presented in Table 5.
\*\*Table 5. MMR rate at Week 24 according to BCR::ABL1 mutation status at baseline and line of therapy of randomized treatment\*\*
| | | |
| --- | --- | --- |
| | \*\*40 mg Scemblix\*\* \*\*twice daily\*\* \*\*n/N (%)\*\* | \*\*500 mg bosutinib\*\* \*\*once daily\*\* \*\*n/N (%)\*\* |
| \*\*BCR::ABL1 mutation status at baseline1\*\* | | |
| No mutation identified | 31/125 (24.8) | 7/63 (11.1) |
| Mutation identified | 6/17 (35.3) | 2/8 (25.0) |
| \*\*Line of therapy of randomized treatment\*\* | | |
| 3 | 24/82 (29.3) | 6/30 (20.0) |
| 4 | 11/44 (25.0) | 4/29 (13.8) |
| ≥5 | 5/31 (16.1) | 0/17 (0.0) |
| n = Number of patients in MMR. N = Number of patients in the subgroup and treatment group with response variable defined. 1Mutation assessment was based on Sanger sequencing. Patients with BCR::ABL1 T315I or V299L mutations or non-evaluable mutation assessment were excluded from the subgroup analysis. | | | |
The MMR rate at 48 weeks was 29.3% (95% CI: 22.32, 37.08) in patients receiving asciminib and 13.2% (95% CI: 6.49, 22.87) in patients receiving bosutinib. The Kaplan-Meier estimated proportion of patients receiving asciminib and maintaining MMR for at least 120 weeks was 97% (95% CI: 88.6, 99.2).
\*\*\*Elderly patients\*\*\*
No overall differences in the safety or efficacy of Scemblix were observed between patients of 65 years of age or above and younger patients. There is an insufficient number of patients of 75 years of age or above to assess whether there are differences in safety or efficacy.
\*\*Paediatric population\*\*
The licensing authority has waived the obligation to submit the results of studies with Scemblix in paediatric patients aged less than 3 years in CML. The licensing authority has deferred the obligation to submit the results of studies with Scemblix in paediatric patients aged from 3 years to less than 18 years in CML (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Asciminib is rapidly absorbed, with median maximum plasma level (Tmax) reached 2 to 3 hours after oral administration, independent of the dose. The geometric mean (geoCV%) of Cmax at steady state is 1781 ng/ml (23%) and 793 ng/ml (49%) following administration of asciminib at 80 mg once-daily and 40 mg twice-daily doses, respectively. The geometric mean (geoCV%) of AUCtau is 5262 ng\\*h/ml (48%) following administration of asciminib at the 40 mg twice-daily dose. PBPK models predict that asciminib absorption is approximately 100%, while bioavailability is approximately 73%.
Asciminib bioavailability may be reduced by co-administration of oral medicinal products containing hydroxypropyl-β-cyclodextrin as an excipient. Co-administration of multiple doses of an itraconazole oral solution containing hydroxypropyl-β-cyclodextrin at a total of 8 g per dose with a 40 mg dose of asciminib decreased asciminib AUCinf by 40.2% in healthy subjects.
\*\*\*Food effect\*\*\*
Food consumption decreases asciminib bioavailability, with a high-fat meal having a higher impact on asciminib pharmacokinetics than a low-fat meal. Asciminib AUC is decreased by 62.3% with a high-fat meal and by 30% with a low-fat meal compared to the fasted state, independent of the dose (see sections 4.2 and 4.5).
\*\*Distribution\*\*
Asciminib apparent volume of distribution at steady state is 111 litres based on population pharmacokinetic analysis. Asciminib is mainly distributed to plasma, with a mean blood-to-plasma ratio of 0.58, independent of the dose. Asciminib is 97.3% bound to human plasma proteins, independent of the dose.
\*\*Biotransformation\*\*
Asciminib is primarily metabolised via CYP3A4-mediated oxidation (36%), UGT2B7-mediated glucuronidation and UGT2B17-mediated glucuronidation (13.3% and 7.8%, respectively). PBPK models predict that asciminib biliary secretion via BCRP accounts for 31.1% of its total systemic clearance. Asciminib is the main circulating component in plasma (92.7% of the administered dose).
\*\*Elimination\*\*
Asciminib is mainly eliminated via faecal excretion, with a minor contribution of the renal route. Eighty and 11% of the asciminib dose were recovered in the faeces and in the urine of healthy subjects, respectively, following oral administration of a single 80 mg dose of [14C]-labelled asciminib. Faecal elimination of unchanged asciminib accounts for 56.7% of the administered dose.
The oral total clearance (CL/F) of asciminib is 6.31 l/hour, based on population pharmacokinetic analysis. The accumulation half-life of asciminib is 5.2 hours at 40 mg twice daily and 80 mg once daily.
\*\*Linearity/non-linearity\*\*
Asciminib exhibits a slight dose over-proportional increase in steady-state exposure (AUC and Cmax) across the dose range of 10 to 200 mg administered once or twice daily.
The geometric mean average accumulation ratio is approximately 2-fold, independent of the dose. Steady-state conditions are achieved within 3 days at the 40 mg twice-daily dose.
\*\*\*In vitro\*\*\* \*\*evaluation of drug interaction potential\*\*
\*\*\*CYP450 and UGT enzymes\*\*\*
\*In vitro\*, asciminib reversibly inhibits CYP3A4/5, CYP2C9 and UGT1A1 at plasma concentrations reached at a total daily dose of 80 mg.
\*\*\*Transporters\*\*\*
Asciminib is a substrate of BCRP and P-gp.
Asciminib inhibits BCRP and P-gp with Ki values of 24.3 and 21.7 micromolar, respectively.
\*\*\*Multiple pathways\*\*\*
Asciminib is metabolised by several pathways, including the CYP3A4, UGT2B7 and UGT2B17 enzymes and biliary secreted by the transporter BCRP. Medicinal products inhibiting or inducing multiple pathways may alter asciminib exposure.
\*\*Special populations\*\*
\*\*\*Gender, race, body weight\*\*\*
Asciminib systemic exposure is not affected by gender, race or body weight to any clinically relevant extent.
\*\*\*Renal impairment\*\*\*
A dedicated renal impairment study including 6 subjects with normal renal function (absolute glomerular filtration rate [aGFR] ≥90 ml/min) and 8 subjects with severe renal impairment not requiring dialysis (aGFR 15 to <30 ml/min) has been conducted. Asciminib AUCinf and Cmax are increased by 56% and 8%, respectively, in subjects with severe renal impairment compared to subjects with normal renal function, following oral administration of a single 40 mg dose of asciminib (see section 4.2). Population pharmacokinetics models indicate an increase in asciminib median steady-state AUC0-24h by 11.5% in subjects with mild to moderate renal impairment, compared to subjects with normal renal function.
\*\*\*Hepatic impairment\*\*\*
A dedicated hepatic impairment study including 8 subjects each with normal hepatic function, mild hepatic impairment (Child-Pugh A score 5-6), moderate hepatic impairment (Child-Pugh B score 7-9) or severe hepatic impairment (Child-Pugh C score 10-15) was conducted. Asciminib AUCinf is increased by 22%, 3% and 66% in subjects with mild, moderate and severe hepatic impairment, respectively, compared to subjects with normal hepatic function, following oral administration of a single 40 mg dose of asciminib (see section 4.2).5.3 Preclinical safety data
Asciminib was evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity and phototoxicity studies.
\*\*Safety pharmacology\*\*
In safety pharmacology studies, asciminib did not have any effect on the central nervous and respiratory systems in rats at doses up to 600 mg/kg/day.
In an \*in vitro\* study, asciminib inhibited the human ether-à-go-go-related gene (hERG) channels with an IC50 of 11.4 micromolar. This value translates into a clinical safety margin at least 200-fold or 100-fold higher when compared to asciminib free Cmax in patients at the 40 mg twice-daily or 80 mg once-daily dose, respectively.
Moderate cardiovascular effects (increased heart rate, decreased systolic pressure, decreased mean arterial pressure, and decreased arterial pulse pressure) were observed in \*in vivo\* cardiac safety studies in dogs. No QTc prolongation was evident in dogs up to the highest asciminib free exposure of 6.3 micromolar.
\*\*Repeat dose toxicity\*\*
Repeat dose toxicity studies identified the pancreas, liver, haematopoietic system, adrenal gland and gastrointestinal tract as target organs of asciminib.
Pancreatic effects (serum amylase and lipase increases, acinar cell lesions) occurred in dogs at AUC exposures below those achieved in patients on 40 mg twice daily or 80 mg once daily. A trend towards recovery was observed.
Elevations in liver enzymes and/or bilirubin were observed in rats, dogs and monkeys. Histopathological hepatic changes (centrilobular hepatocyte hypertrophy, slight bile duct hyperplasia, increased individual hepatocyte necrosis and diffuse hepatocellular hypertrophy) were seen in rats and monkeys. These changes occurred at AUC exposures either equivalent to (rats) or 8- to 18-fold (dogs and monkeys) higher than those achieved in patients on 40 mg twice daily or 80 mg once daily. These changes were fully reversible.
Effects on the haematopoietic system (reduction in red blood cell mass, increased splenic or bone marrow pigment and increased reticulocytes) were consistent with a mild and regenerative, extravascular, haemolytic anaemia in all species. These changes occurred at AUC exposures either equivalent to (rats) or 10- to 14-fold (dogs and monkeys) higher than those achieved in patients on 40 mg twice daily or 80 mg once daily. These changes were fully reversible.
Minimal mucosal hypertrophy/hyperplasia (increase in thickness of the mucosa with frequent elongation of villi) was present in the duodenum of rats at AUC exposures 30-fold or 22-fold higher than those achieved in patients on 40 mg twice daily or 80 mg once daily, respectively. This change was fully reversible.
Minimal or slight hypertrophy of the adrenal gland and mild to moderate decreased vacuolation in the zona fasciculata occurred at AUC exposures either equivalent to (monkeys) or 13- to 19-fold (rats) higher than those achieved in patients on 40 mg twice daily or 80 mg once daily, respectively. These changes were fully reversible.
\*\*Carcinogenicity and mutagenicity\*\*
Asciminib did not have mutagenic, clastogenic or aneugenic potential either \*in vitro\* nor \*in vivo\*.
In a 2 year rat carcinogenicity study, non-neoplastic proliferative changes consisting of ovarian Sertoli cells hyperplasia no asciminib related neoplastic or hyperplastic findings were noted observed in female animals at doses equal to or above 30 mg/kg/day. Benign Sertoli cell tumours in the ovaries were observed in female rats at the highest dose of 66 mg/kg/day. in male or female rats at any dose level. AUC exposures to asciminib in female rats at the highest dose 66 mg/kg/day were generally 8 fold higher than those achieved in patients at the dose of 40 mg twice daily.
The clinical relevance of these findings is currently unknown.
\*\*Reproductive toxicity\*\*
Animal reproduction studies in pregnant rats and rabbits demonstrated that oral administration of asciminib during organogenesis induced embryotoxicity, foetotoxicity and teratogenicity.
In embryo-foetal development studies, pregnant animals received oral doses of asciminib at 25, 150 and 600 mg/kg/day in rats and at 15, 50 and 300 mg/kg/day in rabbits during the period of organogenesis.
In rats, asciminib was not tolerated in maternal animals at 600 mg/kg/day and resulted in the early termination of the dose group. There was no evidence of asciminib-related embryo-foetal death at doses below or equal to 150 mg/kg/day. A dose-related increase in foetal weights at 25 and 150 mg/kg/day was observed. Foetal variations in the urinary tract and skeleton (skull, vertebral column and ribs), indicative of changes in the rate of development, were observed primarily at 150 mg/kg/day. A slight increase in the malformation rate (anasarca and cardiac malformations) and some visceral variants indicative of adverse effects on embryo-foetal development were also observed at 150 mg/kg/day. The maternal no-observed-adverse-effect level (NOAEL) was 150 mg/kg/day and the foetal NOAEL was ≤ 25 mg/kg/day. At 25 mg/kg/day, the AUC exposures were equivalent to or below those achieved in patients at the 40 mg twice-daily or 80 mg once-daily doses, respectively.
In rabbits, 300 mg/kg/day caused morbidity in the maternal animals and resulted in the early termination of the dose group. An increased incidence of resorptions, indicative of embryo-foetal mortality, and a low incidence of cardiac malformations, indicative of teratogenicity, were observed at 50 mg/kg/day. There was no effect on foetal growth. The NOAEL for maternal toxicity was 50 mg/kg/day and the foetal NOAEL was 15 mg/kg/day. At the foetal NOAEL of 15 mg/kg/day, the AUC exposures were equivalent to or below those achieved in patients at the 40 mg twice-daily or 80 mg once-daily doses, respectively.
In the rat fertility study, asciminib did not affect reproductive function in male and female rats. A slight effect on male sperm motility and sperm count was observed at doses of 200 mg/kg/day, likely at AUC exposures 19-fold or 13-fold higher than those achieved in patients at the 40 mg twice-daily and 80 mg once-daily doses, respectively.
\*\*Phototoxicity\*\*
In mice, asciminib showed dose-dependent phototoxic effects starting at 200 mg/kg/day. At the NOAEL of 60 mg/kg/day, exposure based on Cmax in plasma was 15-fold or 6-fold higher than the exposure in patients on 40 mg twice daily or 80 mg once daily, respectively.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Tablet core\*\*
Lactose monohydrate
Microcrystalline cellulose (fine and granular)
Hydroxypropylcellulose
Croscarmellose sodium
Magnesium stearate
Colloidal silicon dioxide
\*\*Tablet coating\*\*
Polyvinyl alcohol
Titanium dioxide (E171)
Talc
Lecithin (E322)
Xanthan gum (E415)
Iron oxide red (E172)
\*\*\*Scemblix 20 mg film-coated tablets only\*\*\*
Iron oxide yellow (E172)
\*\*\*Scemblix 40 mg film-coated tablets only\*\*\*
Iron oxide black (E172)6.2 Incompatibilities
Not applicable.6.3 Shelf life
36 months.6.4 Special precautions for storage
Do not store above 25°C.
Store in the original package in order to protect from moisture.6.5 Nature and contents of container
PCTFE/PVC/Alu blisters in packs containing 20 or 60 film-coated tablets. Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
\*\*Scemblix 20 mg film-coated tablets\*\*
Each film-coated tablet contains asciminib hydrochloride, equivalent to 20 mg asciminib.
\*\*\*Excipients with known effect\*\*\*
Each film-coated tablet contains 43 mg lactose monohydrate.
\*\*Scemblix 40 mg film-coated tablets\*\*
Each film-coated tablet contains asciminib hydrochloride, equivalent to 40 mg asciminib.
\*\*\*Excipients with known effect\*\*\*
Each film-coated tablet contains 86 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Film-coated tablet.
\*\*20 mg film-coated tablets\*\*
Pale yellow, round, biconvex film-coated tablets with bevelled edges of approximately 6 mm diameter, unscored, debossed with company logo on one side and “20” on the other side.
\*\*Scemblix 40 mg film-coated tablets\*\*
Violet white, round, biconvex film-coated tablets with bevelled edges of approximately 8 mm diameter, unscored, debossed with company logo on one side and “40” on the other side.
## Clinical Particulars
4.1 Therapeutic indications
Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.4.2 Posology and method of administration
Treatment with Scemblix should be initiated by a physician knowledgeable in the diagnosis and treatment of patients with chronic myeloid leukaemia.
\*\*Posology\*\*
The recommended total daily dose of Scemblix is 80 mg. Scemblix can be taken orally either as 80 mg once daily at approximately the same time each day or as 40 mg twice daily at approximately 12-hour intervals.
Patients changing from 40 mg twice daily to 80 mg once daily should start taking asciminib once daily approximately 12 hours after the last twice-daily dose, and then continue at 80 mg once daily.
Patients changing from 80 mg once daily to 40 mg twice daily should start taking asciminib twice daily approximately 24 hours after the last once-daily dose and then continue at 40 mg twice daily at approximately 12-hour intervals.
Any change in the dosage regimen is at the prescriber's discretion, as necessary for the management of the patient.
\*\*\*Missed dose\*\*\*
Once-daily dosage regimen: If a dose is missed by more than approximately 12 hours, it should be skipped and the next dose should be taken as scheduled.
Twice-daily dosage regimen: If a dose is missed by more than approximately 6 hours, it should be skipped and the next dose should be taken as scheduled.
\*\*\*Treatment duration\*\*\*
Treatment with asciminib should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs.
\*\*\*Dose adjustments for adverse reactions\*\*\*
For the management of adverse reactions, the dose can be reduced based on individual safety and tolerability, as described in Table 1.
If adverse reactions are effectively managed, asciminib may be resumed as described in Table 1. It should be permanently discontinued in patients unable to tolerate a total daily dose of 40 mg.
\*\*Table 1 Asciminib dose modification\*\*
| | | |
| --- | --- | --- |
| \*\*Starting dose\*\* | \*\*Reduced dose\*\* | \*\*Resumed dose\*\* |
| 80 mg once daily | 40 mg once daily | 80 mg once daily |
| 40 mg twice daily | 20 mg twice daily | 40 mg twice daily |
The recommended dosage modification for the management of selected adverse reactions is shown in Table 2.
\*\*Table 2 Asciminib dose modification schedule for the management of adverse reactions\*\*
| | |
| --- | --- |
| \*\*Adverse reaction\*\* | \*\*Dosage modification\*\* |
| \*\*Thrombocytopenia and/or neutropenia\*\* | |
| ANC <1.0 x 109/l and/or PLT <50 x 109/l | Withhold asciminib until resolved to ANC ≥1 x 109/l and/or PLT ≥50 x 109/l. If resolved: • Within 2 weeks: resume at starting dose. • After more than 2 weeks: resume at reduced dose For recurrent severe thrombocytopenia and/or neutropenia, withhold asciminib until resolved to ANC ≥1 x 109/l and PLT ≥50 x 109/l, then resume at reduced dose. |
| \*\*Asymptomatic amylase and/or lipase elevation\*\* | |
| Elevation >2.0 x ULN | Withhold asciminib until resolved to <1.5 x ULN. • If resolved: resume at reduced dose. If events reoccur at reduced dose, permanently discontinue. • If not resolved: permanently discontinue. Perform diagnostic tests to exclude pancreatitis. |
| \*\*Non-haematological adverse reactions\*\* | |
| Grade 3 or higher adverse reactions1 | Withhold asciminib until resolved to grade 1 or lower. • If resolved: resume at a reduced dose. • If not resolved: permanently discontinue |
| ANC: absolute neutrophil count; PLT: platelets; ULN: upper limit of normal 1Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03. | |
\*\*\*Special populations\*\*\*
\*Elderly\*
No dose adjustment is required in patients aged 65 years or above.
\*Renal impairment\*
No dose adjustment is required in patients with mild, moderate or severe renal impairment (see section 5.2).
\*Hepatic impairment\*
No dose adjustment is required in patients with mild, moderate or severe hepatic impairment (see section 5.2). Since there are no data available in patients with moderate or severe hepatic impairment, caution should be exercised in these patients (see section 4.8 and 5.2).
\*Paediatric population\*
The safety and efficacy of Scemblix in paediatric patients aged below 18 years have not been established. No data are available.
\*\*Method of administration\*\*
Scemblix is for oral use. The tablets should be taken orally without food. Food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib (see sections 4.5 and 5.2).
The film-coated tablets should be swallowed whole with a glass of water and should not be broken, crushed or chewed.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Myelosuppression\*\*
Thrombocytopenia, neutropenia and anaemia occurred in patients receiving asciminib. Severe (NCI CTCAE grade 3 or 4) thrombocytopenia and neutropenia were reported during treatment with asciminib (see section 4.8). Myelosuppression was generally reversible and managed by temporarily withholding treatment. Complete blood counts should be performed every two weeks for the first 3 months of treatment and then monthly thereafter, or as clinically indicated. Patients should be monitored for signs and symptoms of myelosuppression.
Based on the severity of thrombocytopenia and/or neutropenia, the dose should be temporarily withheld, reduced or permanently discontinued (see section 4.2).
\*\*Pancreatic toxicity\*\*
Pancreatitis and asymptomatic elevation of serum lipase and amylase, including severe reactions, occurred in patients receiving asciminib (see section 4.8).
Serum lipase and amylase levels should be assessed monthly during treatment with asciminib, or as clinically indicated. Patients should be monitored for signs and symptoms of pancreatic toxicity. More frequent monitoring should be performed in patients with a history of pancreatitis. If serum lipase and amylase elevation are accompanied by abdominal symptoms, treatment should be temporarily withheld and appropriate diagnostic tests should be considered to exclude pancreatitis (see section 4.2).
Based on the severity of serum lipase and amylase elevation, the dose should be temporarily withheld, reduced or permanently discontinued (see section 4.2).
\*\*QT prolongation\*\*
QT prolongation occurred in patients receiving asciminib (see section 4.8).
It is recommended that an electrocardiogram is performed prior to the start of treatment with asciminib, and monitored during treatment as clinically indicated. Hypokalaemia and hypomagnesaemia should be corrected prior to asciminib administration and monitored during treatment as clinically indicated.
Caution should be exercised when administering asciminib concomitantly with medicinal products with a known risk of torsades de pointes, or in patients who have a history of or predisposition for QTc prolongation or uncontrolled or significant cardiac disease including bradycardia (see sections 4.5 and 5.1).
\*\*Hypertension\*\*
Hypertension, including severe hypertension, occurred in patients receiving asciminib (see section 4.8).
Hypertension should be monitored and managed using standard antihypertensive therapy during treatment with asciminib as clinically indicated.
\*\*Hepatitis B reactivation\*\*
Reactivation of hepatitis B virus (HBV) has occurred in patients who are chronic carriers of this virus following administration of other BCR::ABL1 tyrosine kinase inhibitors (TKIs). Patients should be tested for HBV infection before the start of treatment with asciminib. HBV carriers who require treatment with asciminib should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
\*\*Lactose\*\*
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
\*\*Sodium\*\*
This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially “sodium free”.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Medicinal products that may decrease asciminib plasma concentrations\*\*
\*\*\*Strong CYP3A4 inducers\*\*\*
Co-administration of a strong CYP3A4 inducer in healthy subjects decreased asciminib AUCinf by 14.9% and increased Cmax by 9% in healthy subjects receiving a single asciminib dose of 40 mg. Physiologically-based pharmacokinetic (PBPK) models predict that co-administration of asciminib at 80 mg once daily with rifampicin would decrease asciminib AUCtau and Cmax by 52% and 23%.
Caution should be exercised during concomitant administration of asciminib with strong CYP3A inducers, including, but not limited to, carbamazepine, phenobarbital, phenytoin or St. John's wort (\*Hypericum perforatum\*). Dose adjustment of asciminib is not required.
\*\*Medicinal products that may have their plasma concentrations altered by asciminib\*\*
\*\*\*CYP3A4 substrates with narrow therapeutic index\*\*\*
Co-administration of asciminib with a CYP3A4 substrate (midazolam) increased midazolam AUCinf and Cmax by 28% and 11%, respectively, in healthy subjects receiving asciminib 40 mg twice daily. PBPK models predict that co-administration of asciminib at 80 mg once daily would increase midazolam AUCinf and Cmax by 24% and 17%, respectively.
Caution should be exercised during concomitant administration of asciminib with CYP3A4 substrates known to have a narrow therapeutic index, including, but not limited to, the CYP3A4 substrates fentanyl, alfentanil, dihydroergotamine or ergotamine (see section 5.2). Dose adjustment of asciminib is not required.
\*\*\*CYP2C9 substrates\*\*\*
Co-administration of asciminib with a CYP2C9 substrate (warfarin) increased S-warfarin AUCinf and Cmax by 41% and 8%, respectively, in healthy subjects receiving asciminib 40 mg twice daily. PBPK models predict that co-administration of asciminib at 80 mg once daily would increase S-warfarin AUCinf and Cmax by 52% and 4%, respectively.
Caution should be exercised during concomitant administration of asciminib with CYP2C9 substrates known to have a narrow therapeutic index, including, but not limited to, phenytoin or warfarin (see section 5.2). Dose adjustment of asciminib is not required.
\*\*\*P-gp substrates of narrow therapeutic index\*\*\*
Caution should be exercised during concomitant administration of asciminib with P-gp substrates known to have a narrow therapeutic index, including but not limited to digoxin, dabigatran and colchicine (see section 5.2). Dose adjustment of asciminib is not required.
\*\*\*P-gp substrates\*\*\*\*\*:\*\*
Coadministration of SCEMBLIX with a drug that is a substrate of P-gp may result in a clinically relevant increase in the plasma concentrations of P-gp substrates, where minimal concentration changes may lead to serious toxicities (e.g. P-gp substrates with narrow therapeutic index such as digoxin).
\*\*\*QT prolongation\*\*\*
Caution should be exercised during concomitant administration of asciminib and medicinal products with a known risk of torsades de pointes, including, but not limited to, bepridil, chloroquine, clarithromycin, halofantrine, haloperidol, methadone, moxifloxacin or pimozide (see sections 4.4, 4.8 and 5.1).
\*\*\*Drug-food interactions\*\*\*
The bioavailability of asciminib decreases on consumption of food (see sections 4.2 and 5.2).
\*\*\*Hydroxypropyl-β-cyclodextrin as an excipient (e.g., itraconazole oral solution)\*\*\*
Caution should be exercised during concomitant administration of asciminib with hydroxypropyl-β-cyclodextrin containing oral products (see section 5.2).4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential/contraception\*\*
The pregnancy status of women of childbearing potential should be verified prior to starting treatment with asciminib.
Women of childbearing potential should be advised to use effective contraception during treatment with asciminib and for at least 3 days after stopping treatment and to avoid becoming pregnant while receiving asciminib.
\*\*Pregnancy\*\*
There are no or limited amount of data from the use of asciminib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Asciminib is not recommended for use during pregnancy, or in women of childbearing potential not using contraception. The patient should be advised of a potential risk to the foetus if asciminib is used during pregnancy or if the patient becomes pregnant while taking asciminib.
\*\*Breast-feeding\*\*
It is unknown whether asciminib is excreted in human milk. There are no data on the effects of asciminib on the breast-fed newborn/infant or on milk production. Because of the potential for serious adverse reactions in the breast-fed newborn/infant, breast-feeding is not recommended during treatment and for at least 3 days after stopping treatment with asciminib.
\*\*Fertility\*\*
There are no data on the effect of asciminib on human fertility. In rat fertility studies, asciminib did not affect reproductive function in male and female rats (see section 5.3).4.7 Effects on ability to drive and use machines
Asciminib has no or negligible influence on the ability to drive and use machines. However, it is recommended that patients experiencing dizziness, fatigue or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8).4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The overall safety profile of asciminib has been evaluated in 356 patients with Ph+ CML-in chronic (CP) and accelerated (AP) phases in the pivotal phase III study A2301 (ASCEMBL) and the phase I study X2101. In ASCEMBL, patients received asciminib as monotherapy at a dose of 40 mg twice daily. In X2101, patients received asciminib as monotherapy at doses ranging from 10 to 200 mg twice daily and 80 to 200 mg once daily.
The safety pool (N=356) includes patients receiving asciminib at doses ranging from 10 to 200 mg twice daily and 80 to 200 mg once daily, with 156 patients receiving asciminib at 40 mg twice daily in the pivotal study, and 35 patients receiving 40 mg twice daily and 18 patients receiving 80 mg once daily from study X2101 as a starting dose. In the pooled dataset, the median duration of exposure to asciminib was 167 weeks (range: 0.1 to 349 weeks).
The most common adverse reactions of any grade (incidence ≥20%) in patients receiving asciminib were musculoskeletal pain (38.8%), upper respiratory tract infections (29.5%), fatigue (28.9%), thrombocytopenia (28.1%), headache (26.4%), arthralgia (24.4%), increased pancreatic enzymes (23%), diarrhoea (22.5%), abdominal pain (22.2%), rash (21.6%), hypertension (20.8%) and nausea (20.8%).
The most common adverse reactions of ≥ grade 3 (incidence ≥5%) in patients receiving asciminib were thrombocytopenia (18.5%), neutropenia (15.7%), increased pancreatic enzymes (12.94%), hypertension (11.2%) and anaemia (5.3%).
Serious adverse reactions occurred in 13.2% of patients receiving asciminib. The most frequent serious adverse reactions (incidence ≥1%) were pleural effusion (2.5%), lower respiratory tract infections (2.2%), thrombocytopenia (1.7%), pyrexia (1.4%), pancreatitis (1.1%), abdominal pain (1.1%), non-cardiac chest pain (1.1%) and vomiting (1.1%). The predicted safety profile of asciminib at the 80 mg once-daily dose is similar to the 40 mg twice-daily dose, based on exposure-safety analysis.
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions from clinical studies (Table 3) are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
\*\*Table 3 Adverse reactions observed with asciminib in clinical studies\*\*
| | | |
| --- | --- | --- |
| \*\*System organ class\*\* | \*\*Frequency category\*\* | \*\*Adverse reaction\*\* |
| Infections and infestations | Very common | Upper respiratory tract infection1 |
| Common | Lower respiratory tract infection2, influenza |
| Blood and lymphatic system disorders | Very common | Thrombocytopenia3, neutropenia4, anaemia5 |
| Uncommon | Febrile neutropenia, pancytopenia |
| Immune system disorders | Uncommon | Hypersensitivity |
| Metabolism and nutrition disorders | Very common | Dyslipidaemia6 |
| Common | Decreased appetite |
| Nervous system disorders | Very common | Headache, dizziness |
| Eye disorders | Common | Dry eye, vision blurred |
| Cardiac disorders | Common | Palpitations |
| Vascular disorders | Very common | Hypertension7 |
| Respiratory, thoracic and mediastinal disorders | Very common | Dyspnoea, cough |
| Common | Pleural effusion, non-cardiac chest pain |
| Gastrointestinal disorders | Very common | Pancreatic enzymes increased8, vomiting, diarrhoea, nausea, abdominal pain9,, constipation |
| Common | Pancreatitis10 |
| Hepatobiliary disorders | Very common | Hepatic enzyme increased11 |
| Common | Blood bilirubin increased12 |
| Skin and subcutaneous tissue disorders | Very common | Rash13, pruritis |
| Common | Urticaria |
| Musculoskeletal and connective tissue disorders | Very common | Musculoskeletal pain14, arthralgia |
| General disorders and administration site conditions | Very common | Fatigue15, oedema16, pyrexia17 |
| Investigations | Common | Electrocardiogram QT prolonged, blood creatine phosphokinase increased |
| 1 Upper respiratory tract infection includes: upper respiratory tract infection, nasopharyngitis, pharyngitis and rhinitis. 2 Lower respiratory tract infections includes: pneumonia, bronchitis and tracheobronchitis. 3 Thrombocytopenia includes: thrombocytopenia and platelet count decreased 4 Neutropenia includes: neutropenia and neutrophil count decreased 5 Anaemia includes: anaemia, haemoglobin decreased and normocytic anaemia. 6 Dyslipidaemia includes: hypertriglyceridaemia, blood cholesterol increased, hypercholesterolaemia, blood triglycerides increased, hyperlipidaemia and dyslipidaemia. 7 Hypertension includes: hypertension and blood pressure increased. 8 Pancreatic enzymes increased includes: lipase increased, amylase increased and hyperlipasaemia. 9 Abdominal pain includes: abdominal pain and abdominal pain upper. 10 Pancreatitis includes: pancreatitis and pancreatitis acute. 11 Hepatic enzymes increased includes: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, transaminases increased and hypertransaminasaemia. 12 Blood bilirubin increased includes: blood bilirubin increased, bilirubin conjugated increased and hyperbilirubinaemia. 13 Rash includes: rash, rash maculopapular and rash pruritic. 14 Musculoskeletal pain includes: pain in extremity, back pain, myalgia, bone pain, musculoskeletal pain, neck pain, musculoskeletal chest pain and musculoskeletal discomfort. 15 Fatigue includes: fatigue and asthenia. 16 Oedema includes: oedema and oedema peripheral. 17 Pyrexia includes: pyrexia and body temperature increased. | | |
\*\*Description of selected adverse reactions\*\*
\*\*\*Myelosuppression\*\*\*
Thrombocytopenia occurred in 28.1% patients receiving asciminib, with grade 3 and 4 reactions reported in 6.7% and 11.8% of patients, respectively. Among the patients with thrombocytopenia ≥ grade 3, the median time to first occurrence of reactions was 6.14 weeks (range: 0.14 to 64.14 weeks) with median duration of any occurring reaction of 2 weeks (95% CI, range: 1.43 to 2 weeks). Of the patients with thrombocytopenia, 2.5% permanently discontinued asciminib, while asciminib was temporarily withheld in 12.4% patients due to the adverse reaction.
Neutropenia occurred in 19.7% patients receiving asciminib, with grade 3 and 4 reactions reported in 7.3% and 8.4% of patients, respectively. Among the patients with neutropenia ≥ grade 3, the median time to first occurrence of reactions was 6.14 weeks (range: 0.14 to 180.1 weeks) with median duration of any occurring reaction of 2 weeks (95% CI, range: 1.43 to 2.14 weeks). Of the patients with neutropenia, 1.7% patients permanently discontinued asciminib, while asciminib was temporarily withheld in 9.3% patients due to the adverse reaction.
Anaemia occurred in 13.2% patients receiving asciminib, with grade 3 reactions occurring in 5.3% of patients. Among the patients with anaemia ≥ grade 3, the median time to first occurrence of reactions was 30.43 weeks (range: 0.43 to 207 weeks) with median duration of any occurring reaction of 0.86 weeks (95% CI, range: 0.29 to 1.71 weeks). Of the patients with anaemia, asciminib was temporarily withheld in 0.6% of patients due to the adverse reaction (see section 4.4).
\*\*\*Pancreatic toxicity\*\*\*
Pancreatitis occurred in 2.5% of patients receiving asciminib, with grade 3 reactions occurring in 1.1% of patients. All these reactions occurred in the phase I study (X2101). Of the patients with pancreatitis, 0.6% permanently discontinued asciminib, while asciminib was temporarily withheld in 1.4% of patients due to the adverse reaction. Asymptomatic elevations of serum lipase and amylase occurred in 23% of patients receiving asciminib, with grade 3 and 4 reactions occurring in 10.4% and 2.5% patients, respectively. Of the patients with elevation of pancreatic enzymes, asciminib was permanently discontinued in 2.2% of patients due to the adverse drug reaction. (see section 4.4)
\*\*\*QT prolongation\*\*\*
Electrocardiogram QT prolongation occurred in 1.1% patients receiving asciminib. In the ASCEMBL clinical study, one patient had a prolonged QTcF greater than 500 ms together with more than 60 ms QTcF increase from baseline, and another patient had prolonged QTcF with more than 60 ms QTcF increase from baseline. (See sections 4.4, 4.5 and 5.1).
\*\*\*Hypertension\*\*\*
Hypertension occurred in 20.8% of patients receiving asciminib, with grade 3 and 4 reactions reported in 11% and 0.3% patients, respectively. Among the patients with hypertension ≥ grade 3, the median time to first occurrence of reactions was 29.21 weeks (range: 0.14 to 365 weeks). Of the patients with hypertension, asciminib was temporarily withheld in 0.8% of patients due to the adverse reaction (see section 4.4).
\*\*\*Laboratory abnormalities\*\*\*
Decrease in phosphate levels occurred as a laboratory abnormality in 17.9% (all grades) and 7.1% (grade 3/4) of 156 patients receiving asciminib at 40 mg twice daily.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
There is limited experience of asciminib overdose. In clinical studies, asciminib has been administered at doses up to 280 mg twice daily with no evidence of increased toxicity.
General supportive measures and symptomatic treatment should be initiated in cases of suspected overdose.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors. ATC code: L01EA06
\*\*Mechanism of action\*\*
Asciminib is an oral and potent inhibitor of ABL and BCR::ABL1 tyrosine kinases. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein, by specifically targeting the ABL myristoyl pocket.
\*\*Cardiac electrophysiology\*\*
Asciminib treatment is associated with an exposure-related prolongation of the QT interval.
The correlation between asciminib concentration and the estimated mean change from baseline of the QT interval with Fridericia's correction (ΔQTcF) was evaluated in 239 patients with Ph+ CML or Ph+ acute lymphoblastic leukaemia (ALL) receiving asciminib at doses ranging from 10 to 280 mg twice daily and 80 to 200 mg once daily. The estimated mean ΔQTcF was 3.35 ms (upper bound of 90% CI: 4.43 ms) for the asciminib 40 mg twice-daily dose and 3.64 ms (upper bound of 90% CI: 4.68 ms) for the asciminib 80 mg once daily dose (see sections 4.4, 4.5 and 4.8).
\*\*Clinical efficacy and safety\*\*
\*\*\*Ph+ CML-CP\*\*\*
The clinical efficacy and safety of asciminib in the treatment of patients with Philadelphia chromosome-positive myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors were demonstrated in the multicentre, randomised, active-controlled and open-label phase III study ASCEMBL.
In this study, a total of 233 patients were randomised in a 2:1 ratio and stratified according to major cytogenetic response (MCyR) status at baseline to receive either asciminib 40 mg twice daily (N=157) or bosutinib 500 mg once daily (N=76). Patients continued treatment until unacceptable toxicity or treatment failure occurred. Patients with known presence T315I and/or V299L mutations at any time prior to study entry were not included in ASCEMBL.
Patients with Ph+ CML-CP were 51.5% female and 48.5% male with median age 52 years (range: 19 to 83 years). Of the 233 patients, 18.9% were 65 years or older, while 2.6% were 75 years or older.
Patients were Caucasian (74.7%), Asian (14.2%) and Black (4.3%). Of the 233 patients, 80.7% and 18% had Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, respectively.
Patients who had previously received 2, 3, 4, 5 or more prior lines of TKIs were 48.1%, 31.3%, 14.6% and 6%, respectively. Last TKI was discontinued due to lack of efficacy in 63.9% of patients and to lack of tolerability in 34.8%.
The median duration of treatment was 156 weeks (range: 0.1 to 256.3 weeks) for patients receiving asciminib and 30.5 weeks (range: 1 to 239.3 weeks) for patients receiving bosutinib.
\*Results\*
The primary endpoint of the study was major molecular response rate (MMR) at 24 weeks and the key secondary endpoint was MMR rate at 96 weeks. MMR is defined as BCR::ABL1 IS ratio ≤0.1%. Other secondary endpoints were complete CCyR rate at 24 and 96 weeks, defined as no Philadelphia positive metaphases in bone marrow with a minimum of 20 metaphases examined.
The main efficacy outcomes from the ASCEMBL study are summarised in Table 4.
\*\*Table 4 Efficacy results in patients treated with two or more tyrosine kinase inhibitors (ASCEMBL)\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Efficacy results in patients treated with two or more tyrosine kinase inhibitors (ASCEMBL)\*\* | \*\*40 mg Scemblix twice daily\*\* | \*\*500 mg bosutinib once daily\*\* | \*\*Difference (95% CI)1\*\* | \*\*p-value\*\* |
| MMR rate, % (95% CI) at 24 weeks | \*\*N=157\*\* 25.48 (18.87, 33.04) | \*\*N=76\*\* 13.16 (6.49, 22.87) | 12.24 (2.19, 22.30) | 0.0292 |
| MMR rate, % (95% CI) at 96 weeks | \*\*N = 157\*\* 37.58 (29.99, 45.65) | \*\*N = 76\*\* 15.79 (8.43, 25.96) | 21.74 (10.53, 32.95) | 0.0012 |
| CCyR rate, % (95% CI) at 24 weeks | \*\*N=103\*\*3 40.78 (31.20, 50.9) | \*\*N=62\*\*3 24.19 (14.22, 36.74) | 17.3 (3.62, 30.99) | not formally tested |
| CCyR rate, % (95% CI) at 96 weeks | \*\*N = 1033\*\* 39.81 (30.29, 49.92) | \*\*N = 623\*\* 16.13 (8.02, 27.67) | 23.87 (10.30, 37.43) | not formally tested |
| Major molecular response (MMR) is defined as a BCR::ABL1 ratio ≤0.1% on the International Scale. Complete cytogenetic response (CCyR) is defined as no Philadelphia chromosome metaphases in bone marrow with a minimum of 20 metaphases examined. \*1 Adjusted for the baseline major cytogenetic response status\* \*2 Cochran-Mantel-Haenszel two-sided test stratified by baseline major cytogenetic response status\* \*3 CCyR analysis based on patients who were not in CCyR at baseline\* | | | | |
The predicted MMR rate at 24 weeks for the asciminib 80 mg once-daily dose is comparable to the MMR rate at 24 weeks observed in ASCEMBL with the asciminib 40 mg twice-daily dose, based on exposure response analysis.
In ASCEMBL, 12.7% of patients treated with asciminib and 13.2% of patients receiving bosutinib had one or more BCR::ABL1 mutations detected at baseline. MMR rates by mutation status are presented in Table 5.
\*\*Table 5. MMR rate at Week 24 according to BCR::ABL1 mutation status at baseline and line of therapy of randomized treatment\*\*
| | | |
| --- | --- | --- |
| | \*\*40 mg Scemblix\*\* \*\*twice daily\*\* \*\*n/N (%)\*\* | \*\*500 mg bosutinib\*\* \*\*once daily\*\* \*\*n/N (%)\*\* |
| \*\*BCR::ABL1 mutation status at baseline1\*\* | | |
| No mutation identified | 31/125 (24.8) | 7/63 (11.1) |
| Mutation identified | 6/17 (35.3) | 2/8 (25.0) |
| \*\*Line of therapy of randomized treatment\*\* | | |
| 3 | 24/82 (29.3) | 6/30 (20.0) |
| 4 | 11/44 (25.0) | 4/29 (13.8) |
| ≥5 | 5/31 (16.1) | 0/17 (0.0) |
| n = Number of patients in MMR. N = Number of patients in the subgroup and treatment group with response variable defined. 1Mutation assessment was based on Sanger sequencing. Patients with BCR::ABL1 T315I or V299L mutations or non-evaluable mutation assessment were excluded from the subgroup analysis. | | | |
The MMR rate at 48 weeks was 29.3% (95% CI: 22.32, 37.08) in patients receiving asciminib and 13.2% (95% CI: 6.49, 22.87) in patients receiving bosutinib. The Kaplan-Meier estimated proportion of patients receiving asciminib and maintaining MMR for at least 120 weeks was 97% (95% CI: 88.6, 99.2).
\*\*\*Elderly patients\*\*\*
No overall differences in the safety or efficacy of Scemblix were observed between patients of 65 years of age or above and younger patients. There is an insufficient number of patients of 75 years of age or above to assess whether there are differences in safety or efficacy.
\*\*Paediatric population\*\*
The licensing authority has waived the obligation to submit the results of studies with Scemblix in paediatric patients aged less than 3 years in CML. The licensing authority has deferred the obligation to submit the results of studies with Scemblix in paediatric patients aged from 3 years to less than 18 years in CML (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Asciminib is rapidly absorbed, with median maximum plasma level (Tmax) reached 2 to 3 hours after oral administration, independent of the dose. The geometric mean (geoCV%) of Cmax at steady state is 1781 ng/ml (23%) and 793 ng/ml (49%) following administration of asciminib at 80 mg once-daily and 40 mg twice-daily doses, respectively. The geometric mean (geoCV%) of AUCtau is 5262 ng\\*h/ml (48%) following administration of asciminib at the 40 mg twice-daily dose. PBPK models predict that asciminib absorption is approximately 100%, while bioavailability is approximately 73%.
Asciminib bioavailability may be reduced by co-administration of oral medicinal products containing hydroxypropyl-β-cyclodextrin as an excipient. Co-administration of multiple doses of an itraconazole oral solution containing hydroxypropyl-β-cyclodextrin at a total of 8 g per dose with a 40 mg dose of asciminib decreased asciminib AUCinf by 40.2% in healthy subjects.
\*\*\*Food effect\*\*\*
Food consumption decreases asciminib bioavailability, with a high-fat meal having a higher impact on asciminib pharmacokinetics than a low-fat meal. Asciminib AUC is decreased by 62.3% with a high-fat meal and by 30% with a low-fat meal compared to the fasted state, independent of the dose (see sections 4.2 and 4.5).
\*\*Distribution\*\*
Asciminib apparent volume of distribution at steady state is 111 litres based on population pharmacokinetic analysis. Asciminib is mainly distributed to plasma, with a mean blood-to-plasma ratio of 0.58, independent of the dose. Asciminib is 97.3% bound to human plasma proteins, independent of the dose.
\*\*Biotransformation\*\*
Asciminib is primarily metabolised via CYP3A4-mediated oxidation (36%), UGT2B7-mediated glucuronidation and UGT2B17-mediated glucuronidation (13.3% and 7.8%, respectively). PBPK models predict that asciminib biliary secretion via BCRP accounts for 31.1% of its total systemic clearance. Asciminib is the main circulating component in plasma (92.7% of the administered dose).
\*\*Elimination\*\*
Asciminib is mainly eliminated via faecal excretion, with a minor contribution of the renal route. Eighty and 11% of the asciminib dose were recovered in the faeces and in the urine of healthy subjects, respectively, following oral administration of a single 80 mg dose of [14C]-labelled asciminib. Faecal elimination of unchanged asciminib accounts for 56.7% of the administered dose.
The oral total clearance (CL/F) of asciminib is 6.31 l/hour, based on population pharmacokinetic analysis. The accumulation half-life of asciminib is 5.2 hours at 40 mg twice daily and 80 mg once daily.
\*\*Linearity/non-linearity\*\*
Asciminib exhibits a slight dose over-proportional increase in steady-state exposure (AUC and Cmax) across the dose range of 10 to 200 mg administered once or twice daily.
The geometric mean average accumulation ratio is approximately 2-fold, independent of the dose. Steady-state conditions are achieved within 3 days at the 40 mg twice-daily dose.
\*\*\*In vitro\*\*\* \*\*evaluation of drug interaction potential\*\*
\*\*\*CYP450 and UGT enzymes\*\*\*
\*In vitro\*, asciminib reversibly inhibits CYP3A4/5, CYP2C9 and UGT1A1 at plasma concentrations reached at a total daily dose of 80 mg.
\*\*\*Transporters\*\*\*
Asciminib is a substrate of BCRP and P-gp.
Asciminib inhibits BCRP and P-gp with Ki values of 24.3 and 21.7 micromolar, respectively.
\*\*\*Multiple pathways\*\*\*
Asciminib is metabolised by several pathways, including the CYP3A4, UGT2B7 and UGT2B17 enzymes and biliary secreted by the transporter BCRP. Medicinal products inhibiting or inducing multiple pathways may alter asciminib exposure.
\*\*Special populations\*\*
\*\*\*Gender, race, body weight\*\*\*
Asciminib systemic exposure is not affected by gender, race or body weight to any clinically relevant extent.
\*\*\*Renal impairment\*\*\*
A dedicated renal impairment study including 6 subjects with normal renal function (absolute glomerular filtration rate [aGFR] ≥90 ml/min) and 8 subjects with severe renal impairment not requiring dialysis (aGFR 15 to <30 ml/min) has been conducted. Asciminib AUCinf and Cmax are increased by 56% and 8%, respectively, in subjects with severe renal impairment compared to subjects with normal renal function, following oral administration of a single 40 mg dose of asciminib (see section 4.2). Population pharmacokinetics models indicate an increase in asciminib median steady-state AUC0-24h by 11.5% in subjects with mild to moderate renal impairment, compared to subjects with normal renal function.
\*\*\*Hepatic impairment\*\*\*
A dedicated hepatic impairment study including 8 subjects each with normal hepatic function, mild hepatic impairment (Child-Pugh A score 5-6), moderate hepatic impairment (Child-Pugh B score 7-9) or severe hepatic impairment (Child-Pugh C score 10-15) was conducted. Asciminib AUCinf is increased by 22%, 3% and 66% in subjects with mild, moderate and severe hepatic impairment, respectively, compared to subjects with normal hepatic function, following oral administration of a single 40 mg dose of asciminib (see section 4.2).5.3 Preclinical safety data
Asciminib was evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity and phototoxicity studies.
\*\*Safety pharmacology\*\*
In safety pharmacology studies, asciminib did not have any effect on the central nervous and respiratory systems in rats at doses up to 600 mg/kg/day.
In an \*in vitro\* study, asciminib inhibited the human ether-à-go-go-related gene (hERG) channels with an IC50 of 11.4 micromolar. This value translates into a clinical safety margin at least 200-fold or 100-fold higher when compared to asciminib free Cmax in patients at the 40 mg twice-daily or 80 mg once-daily dose, respectively.
Moderate cardiovascular effects (increased heart rate, decreased systolic pressure, decreased mean arterial pressure, and decreased arterial pulse pressure) were observed in \*in vivo\* cardiac safety studies in dogs. No QTc prolongation was evident in dogs up to the highest asciminib free exposure of 6.3 micromolar.
\*\*Repeat dose toxicity\*\*
Repeat dose toxicity studies identified the pancreas, liver, haematopoietic system, adrenal gland and gastrointestinal tract as target organs of asciminib.
Pancreatic effects (serum amylase and lipase increases, acinar cell lesions) occurred in dogs at AUC exposures below those achieved in patients on 40 mg twice daily or 80 mg once daily. A trend towards recovery was observed.
Elevations in liver enzymes and/or bilirubin were observed in rats, dogs and monkeys. Histopathological hepatic changes (centrilobular hepatocyte hypertrophy, slight bile duct hyperplasia, increased individual hepatocyte necrosis and diffuse hepatocellular hypertrophy) were seen in rats and monkeys. These changes occurred at AUC exposures either equivalent to (rats) or 8- to 18-fold (dogs and monkeys) higher than those achieved in patients on 40 mg twice daily or 80 mg once daily. These changes were fully reversible.
Effects on the haematopoietic system (reduction in red blood cell mass, increased splenic or bone marrow pigment and increased reticulocytes) were consistent with a mild and regenerative, extravascular, haemolytic anaemia in all species. These changes occurred at AUC exposures either equivalent to (rats) or 10- to 14-fold (dogs and monkeys) higher than those achieved in patients on 40 mg twice daily or 80 mg once daily. These changes were fully reversible.
Minimal mucosal hypertrophy/hyperplasia (increase in thickness of the mucosa with frequent elongation of villi) was present in the duodenum of rats at AUC exposures 30-fold or 22-fold higher than those achieved in patients on 40 mg twice daily or 80 mg once daily, respectively. This change was fully reversible.
Minimal or slight hypertrophy of the adrenal gland and mild to moderate decreased vacuolation in the zona fasciculata occurred at AUC exposures either equivalent to (monkeys) or 13- to 19-fold (rats) higher than those achieved in patients on 40 mg twice daily or 80 mg once daily, respectively. These changes were fully reversible.
\*\*Carcinogenicity and mutagenicity\*\*
Asciminib did not have mutagenic, clastogenic or aneugenic potential either \*in vitro\* nor \*in vivo\*.
In a 2 year rat carcinogenicity study, non-neoplastic proliferative changes consisting of ovarian Sertoli cells hyperplasia no asciminib related neoplastic or hyperplastic findings were noted observed in female animals at doses equal to or above 30 mg/kg/day. Benign Sertoli cell tumours in the ovaries were observed in female rats at the highest dose of 66 mg/kg/day. in male or female rats at any dose level. AUC exposures to asciminib in female rats at the highest dose 66 mg/kg/day were generally 8 fold higher than those achieved in patients at the dose of 40 mg twice daily.
The clinical relevance of these findings is currently unknown.
\*\*Reproductive toxicity\*\*
Animal reproduction studies in pregnant rats and rabbits demonstrated that oral administration of asciminib during organogenesis induced embryotoxicity, foetotoxicity and teratogenicity.
In embryo-foetal development studies, pregnant animals received oral doses of asciminib at 25, 150 and 600 mg/kg/day in rats and at 15, 50 and 300 mg/kg/day in rabbits during the period of organogenesis.
In rats, asciminib was not tolerated in maternal animals at 600 mg/kg/day and resulted in the early termination of the dose group. There was no evidence of asciminib-related embryo-foetal death at doses below or equal to 150 mg/kg/day. A dose-related increase in foetal weights at 25 and 150 mg/kg/day was observed. Foetal variations in the urinary tract and skeleton (skull, vertebral column and ribs), indicative of changes in the rate of development, were observed primarily at 150 mg/kg/day. A slight increase in the malformation rate (anasarca and cardiac malformations) and some visceral variants indicative of adverse effects on embryo-foetal development were also observed at 150 mg/kg/day. The maternal no-observed-adverse-effect level (NOAEL) was 150 mg/kg/day and the foetal NOAEL was ≤ 25 mg/kg/day. At 25 mg/kg/day, the AUC exposures were equivalent to or below those achieved in patients at the 40 mg twice-daily or 80 mg once-daily doses, respectively.
In rabbits, 300 mg/kg/day caused morbidity in the maternal animals and resulted in the early termination of the dose group. An increased incidence of resorptions, indicative of embryo-foetal mortality, and a low incidence of cardiac malformations, indicative of teratogenicity, were observed at 50 mg/kg/day. There was no effect on foetal growth. The NOAEL for maternal toxicity was 50 mg/kg/day and the foetal NOAEL was 15 mg/kg/day. At the foetal NOAEL of 15 mg/kg/day, the AUC exposures were equivalent to or below those achieved in patients at the 40 mg twice-daily or 80 mg once-daily doses, respectively.
In the rat fertility study, asciminib did not affect reproductive function in male and female rats. A slight effect on male sperm motility and sperm count was observed at doses of 200 mg/kg/day, likely at AUC exposures 19-fold or 13-fold higher than those achieved in patients at the 40 mg twice-daily and 80 mg once-daily doses, respectively.
\*\*Phototoxicity\*\*
In mice, asciminib showed dose-dependent phototoxic effects starting at 200 mg/kg/day. At the NOAEL of 60 mg/kg/day, exposure based on Cmax in plasma was 15-fold or 6-fold higher than the exposure in patients on 40 mg twice daily or 80 mg once daily, respectively.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Tablet core\*\*
Lactose monohydrate
Microcrystalline cellulose (fine and granular)
Hydroxypropylcellulose
Croscarmellose sodium
Magnesium stearate
Colloidal silicon dioxide
\*\*Tablet coating\*\*
Polyvinyl alcohol
Titanium dioxide (E171)
Talc
Lecithin (E322)
Xanthan gum (E415)
Iron oxide red (E172)
\*\*\*Scemblix 20 mg film-coated tablets only\*\*\*
Iron oxide yellow (E172)
\*\*\*Scemblix 40 mg film-coated tablets only\*\*\*
Iron oxide black (E172)6.2 Incompatibilities
Not applicable.6.3 Shelf life
36 months.6.4 Special precautions for storage
Do not store above 25°C.
Store in the original package in order to protect from moisture.6.5 Nature and contents of container
PCTFE/PVC/Alu blisters in packs containing 20 or 60 film-coated tablets. Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
